Latest filing published 16 Mar 2026 for Supernus Pharmaceuticals, INC., €235k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Frederick M. Hudson (board member) discloses dealings in Supernus Pharmaceuticals, Inc. to SEC (Form 4). We count 12 filings; the first trade dates from 19 February 2022 and the latest from 12 March 2026.
The open-market record consists of 3 sales worth €799k, with no purchase. The rest of the record consists of 5 share grants and 4 option exercises. So far in 2026, the count stands at no purchases and 1 sale.
The record was last updated on 16 March 2026 with an open-market sale (€235k) in Supernus Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations